303 related articles for article (PubMed ID: 17636556)
1. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
Debes A; Bauer M; Kremer S
Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1038-47. PubMed ID: 17636556
[TBL] [Abstract][Full Text] [Related]
2. Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials
.
Frenzel W; Wietek S; Svae TE; Debes A; Svorc D
Int J Clin Pharmacol Ther; 2016 Nov; 54(11):847-855. PubMed ID: 27719744
[TBL] [Abstract][Full Text] [Related]
3. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura.
Bussel JB; Hanna K;
Am J Hematol; 2007 Mar; 82(3):192-8. PubMed ID: 17109385
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.
van der Meer JW; van Beem RT; Robak T; Deptala A; Strengers PF
Vox Sang; 2011 Aug; 101(2):138-46. PubMed ID: 21749402
[TBL] [Abstract][Full Text] [Related]
6. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency.
Aghamohammadi A; Farhoudi A; Nikzad M; Moin M; Pourpak Z; Rezaei N; Gharagozlou M; Movahedi M; Atarod L; Afshar AA; Bazargan N; Hosseinpoor AR
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):60-4. PubMed ID: 14756466
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and safety of the intravenous immunoglobulin octagam
Wietek S; Svorc D; Debes A; Svae TE
Hematology; 2018 May; 23(4):242-247. PubMed ID: 29020871
[TBL] [Abstract][Full Text] [Related]
8. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases.
Ochs HD; Pinciaro PJ;
J Clin Immunol; 2004 May; 24(3):309-14. PubMed ID: 15114062
[TBL] [Abstract][Full Text] [Related]
9. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.
Manlhiot C; Tyrrell PN; Liang L; Atkinson AR; Lau W; Feldman BM
Pediatrics; 2008 Mar; 121(3):e626-30. PubMed ID: 18299304
[TBL] [Abstract][Full Text] [Related]
10. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature.
Schiavotto C; Ruggeri M; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):35-40. PubMed ID: 8039756
[TBL] [Abstract][Full Text] [Related]
11. Human immunoglobulin (KIOVIG®/GAMMAGARD LIQUID®) for immunodeficiency and autoimmune diseases: an observational cohort study.
Blažek B; Misbah SA; Soler-Palacin P; McCoy B; Leibl H; Engl W; Empson V; Gelmont D; Nikolov N
Immunotherapy; 2015; 7(7):753-63. PubMed ID: 25865232
[TBL] [Abstract][Full Text] [Related]
12. Adverse reactions of intravenous immunoglobulin.
Al-Wahadneh AM; Khriesat IA; Kuda EH
Saudi Med J; 2000 Oct; 21(10):953-6. PubMed ID: 11369961
[TBL] [Abstract][Full Text] [Related]
13. Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions.
Rigas M; Tandan R; Sterling RJ
J Clin Neuromuscul Dis; 2008 Dec; 10(2):52-5. PubMed ID: 19169090
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of Flebogammadif, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura.
Julia A; Kovaleva L; Loria S; Alberca I; Hernandez F; Sandoval V; Sierra J; Vidaller A; Ayguasanosa J; Carretero M
Transfus Med; 2009 Oct; 19(5):260-8. PubMed ID: 19747289
[TBL] [Abstract][Full Text] [Related]
15. A prospective controlled crossover trial of a new presentation (10% vs. 5%) of a heat-treated intravenous immunoglobulin.
Matamoros N; De Gracia J; Hernández F; Pons J; Alvarez A; Jiménez V
Int Immunopharmacol; 2005 Mar; 5(3):619-26. PubMed ID: 15683857
[TBL] [Abstract][Full Text] [Related]
16. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
17. Safety monitoring of the intravenous immunoglobulin preparation Intratect® in primary and secondary immunodeficiencies: a prospective non-interventional study.
Bauhofer A; Dietrich RL; Schmeidl R
Int J Clin Pharmacol Ther; 2015 Jan; 53(1):21-31. PubMed ID: 25345431
[TBL] [Abstract][Full Text] [Related]
18. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
Björkander J; Nikoskelainen J; Leibl H; Lanbeck P; Wallvik J; Lumio JT; Braconier JH; Pavlova BG; Birthistle K; Engl W; Walter S; Ehrlich HJ
Vox Sang; 2006 May; 90(4):286-93. PubMed ID: 16635071
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia.
Robak T; Mainau C; Pyringer B; Chojnowski K; Warzocha K; Dmoszynska A; Straub J; Imbach P
Hematology; 2010 Oct; 15(5):351-9. PubMed ID: 20863431
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of patients with primary antibody deficiencies in Germany].
Borte M; Oertelt C; Högy B
Klin Padiatr; 2005; 217(5):276-80. PubMed ID: 16167275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
